Abstract
Many of the links between the genotype and phenotype in hypertrophic cardiomyopathy remain unexplained. In this unique longitudinal study we have investigated a patient with classical clinical phenotypic features of hypertrophic obstructive cardiomyopathy, with a known mutation in MYBPC3, the most commonly affected gene in this disease. By collecting cardiac tissue from the patient at the time of surgical myectomy for relief of left ventricular outflow tract obstruction, we have been able to examine the structure of the myocytes and the functional differences that occur in MyBP-C mutated HCM cardiac tissue from single protein level, onto single cardiomyocyte contractility, through to whole organ function as assessed clinically by echocardiography.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Belus A, Piroddi N, Scellini B, Tesi C, Amati GD, Girolami F, Yacoub M, Cecchi F, Olivotto I, Poggesi C (2008a) The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J Physiol 586(Pt 15):3639–3644
Belus A, Piroddi N, Scellini B, Tesi C, Olivotto I, Girolami F, Yacoub MH, Cecchi F, Poggesi C (2008b) Is fast cross-bridge detachment a common feature to MYH7 and MYBP3 FHC-associated mutations in human cardiac myofibrils? Biophys J 94:1461
Carballo S, Copeland O, Jacques A, Livesey K, Redwood C, Watkins H, Marston S (2008) Evidence for haploinsufficiency as the mechanism of action of MyBP-C mutations that cause HCM. J Mol Cell Cardiol 44(4):768. doi:10.1016/j.yjmcc.2008.02.136
Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE (1995) Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 92(9):2540–2549
Elliott PM, Gimeno JR, Tome MT, Shah J, Ward D, Thaman R, Mogensen J, McKenna WJ (2006) Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 27(16):1933–1941. doi:10.1093/eurheartj/ehl041
Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, Sachdev B, Thaman R, McKenna WJ (2002) Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 23(20):1617–1624. doi:10.1053/euhj.2002.3285
Gallon C, Jacques A, Messer A, Tsang V, McKenna W, Marston S (2007) Altered functions and post-translational modification of contractile proteins in myectomy samples from HOCM patients. J Mol Cell Cardiol 42(Supplement 1):S167. doi:10.1016/j.yjmcc.2007.03.437
Gallon CE, Garcia E, Kikonda-Kanda G, Messer AE, Harding S, Marston S (2008) Cellular dysfunction and altered contractile protein post-translational modification in hypertrophic cardiomyopathy septal tissue. J Mol Cell Cardiol 44(4):746. doi:10.1016/j.yjmcc.2008.02.084
Gray R, Jacques A, Peters N, McKenna W, Walker J, McIntyre H, Fry CH (2005) Electromechanical properties of isolated myocardium from ptients with hypertrophic obstructive cardiomyopathy (HOCM). Circulation 112(17 suppl S):U149
Hamdani N, Kooij V, van Dijk S, Merkus D, Paulus WJ, Remedios CD, Duncker DJ, Stienen GJ, van der Velden J (2008) Sarcomeric dysfunction in heart failure. Cardiovasc Res 77(4):649–658. doi:10.1093/cvr/cvm079
Hofmann PA, Hartzell HC, Moss RL (1991) Alterations in Ca2+ sensitive tension due to partial extraction of C-protein from rat skinned cardiac myocytes and rabbit skeletal muscle fibers. J Gen Physiol 97(6):1141–1163. doi:10.1085/jgp.97.6.1141
Hoskins AC, Jacques A, McKenna W, Tsang V, Remedios CD, Marston S, Kentish JC (2008) Altered contractile function in hypertrophied human myocardium (Abstracts ISHR American Sect. 2008). J Mol Cell Cardiol 44(6):S1–S61. doi:10.1016/j.yjmcc.2008.05.013
Jacques, A., Messer, A., Tsang, V., McKenna, W., Marston, S. (2006). Evidence for reduced troponin I phosphorylation and altered troponin function in patients with hypertrophic obstructive cardiomyopathy. Biophysical Journal 2006 Conference proceedings
Jacques A, Briceno N, Messer A, Gallon C, Jalizadeh S, Garcia E, Kikonda-Kanda G, Goddard J, Harding S, Watkins H, Tsang V, McKenna W, Marston S (2008a) The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy. Cardiovasc Res 79:481–491. doi:10.1093/cvr/cvn094
Jacques A, Copeland O, Messer A, Gallon C, King C, McKenna W, Tsang V, Marston S (2008b) Myosin binding protein C phosphorylation in normal, hypertrophic and failing human heart muscle. J Mol Cell Cardiol 45:209–216. doi:10.1016/j.yjmcc.2008.05.020
Kirschner SE, Becker E, Antognozzi M, Kubis HP, Francino A, Navarro-Lopez F, Bit-Avragim N, Perrot A, Mirrakhimov MM, Osterziel KJ, McKenna WJ, Brenner B, Kraft T (2005) Hypertrophic cardiomyopathy-related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells. Am J Physiol Heart Circ Physiol 288(3):H1242–H1251. doi:10.1152/ajpheart.00686.2004
Knollmann BC, Potter JD (2001) Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. Trends Cardiovasc Med 11:206–212. doi:10.1016/S1050-1738(01)00115-3
Kohler J, Winkler G, Schulte T, McKenna W, Brenner B, Kraft T (2002) Mutation of the myosin converter domain alters cross-bridge elasticity. Proc Natl Acad Sci USA 99(6):3557–3562. doi:10.1073/pnas.062415899
Kulikovskaya I, McClellan G, Levine R, Winegrad S (2003) Effect of extraction of myosin binding protein C on contractility of rat heart. Am J Physiol Heart Circ Physiol 285(2):H857–H865
Messer AE, Jacques AM, Marston SB (2007) Troponin phosphorylation and regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol 42(1):247–259. doi:10.1016/j.yjmcc.2006.08.017
Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, Redwood DR (1975) Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 52(1):88–102
Palmiter KA, Tyska MJ, Haeberle JR, Alpert NR, Fananapazir L, Warshaw DM (2000) R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Musc Res Cell Motil 21(7):609–620. doi:10.1023/A:1005678905119
Redwood CS, Moolman-Smook JC, Watkins H (1999) Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 44:20–36. doi:10.1016/S0008-6363(99)00213-8
Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Duborg O, Burban M, Geffet J-P, Millaire A, Desnos M, Schwartz K, Hainque B, Komadja M (2003) Hypertrophic cardiomyopathy distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107:2227–2232. doi:10.1161/01.CIR.0000066323.15244.54
Robinson P, Mirza M, Knott A, Abdulrazzak H, Willott R, Marston S, Watkins H, Redwood C (2002) Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy. J Biol Chem 277:40710–40716. doi:10.1074/jbc.M203446200
Robinson P, Griffiths PJ, Watkins H, Redwood CS (2007) Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ Res 101(12):1266–1273. doi:10.1161/CIRCRESAHA.107.156380
Tardiff JC (2005) Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 10(3):237–248. doi:10.1007/s10741-005-5253-5
van der Velden J, Papp Z, Zaremba R, Boontje NM, de Jong JW, Owen VJ, Burton PB, Goldmann P, Jaquet K, Stienen GJ (2003) Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res 57(1):37–47. doi:10.1016/S0008-6363(02)00606-5
Van Driest SL, Jaeger MA, Ommen SR, Will ML, Gersh BJ, Tajik AJ, Ackerman MJ (2004a) Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 44(3):602–610. doi:10.1016/j.jacc.2004.04.039
Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ (2004b) Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 44(9):1903–1910. doi:10.1016/j.jacc.2004.07.045
Acknowledgments
We are grateful to for Prof. C. Dos Remedios (University of Sydney, Australia) for supplying the non-failing donor heart tissue. This work was supported by grants FS/03109/16314, RG/02010, PG/07/067 and FS/03/116 from the British Heart Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jacques, A., Hoskins, A.C., Kentish, J.C. et al. From genotype to phenotype: a longitudinal study of a patient with hypertrophic cardiomyopathy due to a mutation in the MYBPC3 gene. J Muscle Res Cell Motil 29, 239–246 (2008). https://doi.org/10.1007/s10974-009-9174-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10974-009-9174-0